Cas no 5627-05-4 (5,6-Dihydrouridine)
5,6-Dihydrouridine Chemical and Physical Properties
Names and Identifiers
-
- Uridine, 5,6-dihydro-
- 5,6-DIHYDROURIDINE
- 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3-diazinane-2,4-dione
- 3,4-Dihydrouridine
- 5,6-Dihydrouridin
- Dihydrouridine
- Uridine,5,6-dihydro
- dihydro-1-beta-delta-ribofuranosyl-2,4(1H,3H)-Pyrimidinedione
- SCHEMBL40762
- Uridine-t
- dihydro-1-b-D-ribofuranosyl-2,4(1H,3H)-Pyrimidinedione
- 1-((2R,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)dihydropyrimidine-2,4(1H,3H)-dione
- AKOS027447507
- MFCD00047490
- PS-11123
- CS-0059431
- CHEMBL3237555
- 5627-05-4
- D86457
- UNII-0D5FR359JO
- NS00127301
- BDBM50007037
- 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one
- Q413063
- HY-113047
- DTXSID6021329
- 2,4(1H,3H)-Pyrimidinedione, dihydro-1-.beta.-D-ribofuranosyl-
- CHEBI:23774
- 0D5FR359JO
- 1-beta-D-ribofuranosylhydrouracil
- Hydrouracil, 1-.beta.-D-ribofuranosyl-
- Dihydro-1-ss-D-ribofuranosyl-2,4(1H,3H)-pyrimidinedione; Dihydrouridine; 1-ss-D-Ribofuranosyl-hydrouracil;
- 1-b-D-Ribofuranosylhydrouracil
- 5,6-Dihydrouridine
-
- MDL： MFCD00063468
- Inchi： 1S/C9H14N2O6/c12-3-4-6(14)7(15)8(17-4)11-2-1-5(13)10-9(11)16/h4,6-8,12,14-15H,1-3H2,(H,10,13,16)/t4-,6-,7-,8-/m1/s1
- InChI Key： ZPTBLXKRQACLCR-XVFCMESISA-N
- SMILES： O1[C@H](CO)[C@H]([C@H]([C@@H]1N1C(NC(CC1)=O)=O)O)O
Computed Properties
- Exact Mass: 248.10100
- Monoisotopic Mass: 246.08518617g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 4
- Hydrogen Bond Acceptor Count: 8
- Heavy Atom Count: 17
- Rotatable Bond Count: 2
- Complexity: 335
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 4
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- XLogP3: -2.1
- Topological Polar Surface Area: 119?2
Experimental Properties
- PSA: 122.49000
- LogP: -2.57420
5,6-Dihydrouridine Security Information
- Storage Condition：Please store the product under the recommended conditions in the Certificate of Analysis.
5,6-Dihydrouridine Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| abcr | AB549356-250 mg |
Dihydrouridine, 95%; . |
5627-05-4 | 95% | 250mg |
€135.50 | 2023-06-14 | |
| abcr | AB549356-1 g |
Dihydrouridine, 95%; . |
5627-05-4 | 95% | 1g |
€305.50 | 2023-06-14 | |
| abcr | AB549356-5 g |
Dihydrouridine, 95%; . |
5627-05-4 | 95% | 5g |
€985.50 | 2023-06-14 | |
| Apollo Scientific | OR17694-250mg |
5,6-Dihydrouridine |
5627-05-4 | 95% | 250mg |
￡58.00 | 2025-02-19 | |
| Apollo Scientific | OR17694-1g |
5,6-Dihydrouridine |
5627-05-4 | 95% | 1g |
￡149.00 | 2025-02-19 | |
| Apollo Scientific | OR17694-5g |
5,6-Dihydrouridine |
5627-05-4 | 95% | 5g |
￡509.00 | 2025-02-19 | |
| SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd. | D885032-5mg |
5,6-Dihydrouridine |
5627-05-4 | ≥99% | 5mg |
￥1,008.00 | 2022-01-14 | |
| SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd. | X81055-5mg |
5,6-Dihydrouridine |
5627-05-4 | ≥99% | 5mg |
￥768.0 | 2023-09-05 | |
| ChemScence | CS-0059431-5mg |
5,6-Dihydrouridine |
5627-05-4 | 99.87% | 5mg |
$120.0 | 2021-09-02 | |
| WU HAN AN JIE KAI Biomedical Technology Co., Ltd. | ajce51246-5mg |
5,6-Dihydrouridine |
5627-05-4 | 98% | 5mg |
￥1069.00 | 2023-09-07 |
5,6-Dihydrouridine Suppliers
Audited Supplier
Audited Supplier
5,6-Dihydrouridine Related Literature
-
Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
-
Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
-
Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
-
Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
-
Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
Additional information on 5,6-Dihydrouridine
Introduction to 5,6-Dihydrouridine (CAS No. 5627-05-4): Applications and Recent Research Developments
5,6-Dihydrouridine, with the chemical identifier CAS No. 5627-05-4, is a naturally occurring nucleoside derivative that has garnered significant attention in the field of pharmaceutical and biochemical research. This compound, characterized by its unique structural properties, exhibits a variety of biological activities that make it a promising candidate for therapeutic applications. The recent advancements in understanding its mechanisms of action and potential benefits have further solidified its role in modern medicine.
The molecular structure of 5,6-Dihydrouridine consists of a uracil base attached to a ribose sugar, with the hydroxy groups at the 5' and 6' positions modified to dihydro forms. This structural modification imparts distinct biochemical properties that differentiate it from its parent compound, uridine. The dihydro configuration enhances its solubility and stability, making it more suitable for formulation into various pharmaceutical products.
One of the most compelling aspects of 5,6-Dihydrouridine is its potential as an antioxidant and cytoprotective agent. Studies have demonstrated that this compound can scavenge reactive oxygen species (ROS) and mitigate oxidative stress, which are implicated in numerous pathological conditions such as neurodegenerative diseases, cardiovascular disorders, and inflammation-related illnesses. The ability of 5,6-Dihydrouridine to protect cells from oxidative damage has been observed in both in vitro and in vivo models, suggesting its therapeutic efficacy.
Recent research has also highlighted the role of 5,6-Dihydrouridine in enhancing cellular energy metabolism. By acting as a precursor for uridine monophosphate (UMP), which is a key intermediate in the synthesis of nucleotides, this compound supports the replenishment of nucleotide pools essential for DNA and RNA biosynthesis. This function is particularly relevant in tissues with high turnover rates, such as hematopoietic cells and neurons. Furthermore, studies indicate that 5,6-Dihydrouridine can improve mitochondrial function by increasing ATP production, thereby contributing to overall cellular health.
The therapeutic potential of 5,6-Dihydrouridine extends to its applications in managing metabolic disorders. Emerging evidence suggests that this compound can modulate glucose metabolism by enhancing insulin sensitivity and improving glycemic control. In preclinical studies conducted on animal models of diabetes, administration of 5,6-Dihydrouridine has shown promising results in reducing hyperglycemia and preventing the development of diabetic complications. These findings position 5,6-Dihydrouridine as a candidate for developing novel treatments for diabetes and related metabolic syndromes.
Another area where 5,6-Dihydrouridine has shown promise is in neuroprotection. Oxidative stress and mitochondrial dysfunction are key pathological features in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Research indicates that 5,6-Dihydrouridine can mitigate these pathological processes by protecting neuronal cells from damage caused by ROS and restoring mitochondrial health. Additionally, studies have explored its potential role in modulating neurotransmitter systems, which could have implications for treating cognitive decline and neuroinflammation.
The pharmacokinetic properties of 5,6-Dihydrouridine have also been extensively studied to optimize its delivery and efficacy. Unlike some nucleoside analogs that require complex formulations or undergo rapid degradation, 5,6-Dihydrouridine exhibits favorable pharmacokinetic characteristics due to its enhanced solubility and stability. This makes it an attractive candidate for oral administration or incorporation into various drug delivery systems designed for targeted therapy.
In conclusion,5,6-Dihydrouridine (CAS No. 5627-05-4) represents a versatile compound with significant therapeutic potential across multiple domains of medicine. Its ability to act as an antioxidant,cytoprotective agent,metabolic modulator,and neuroprotective agent positions it as a valuable asset in the development of novel treatments for chronic diseases. The ongoing research into its mechanisms of action and clinical applications continues to expand our understanding of its benefits,making it a subject of great interest among scientists and clinicians alike.
5627-05-4 (5,6-Dihydrouridine) Related Products
- 24514-48-5(Uridine, 5,6-dihydro-5,6-dihydroxy-)
- 36675-91-9(1-pentofuranosyldihydropyrimidine-2,4,5(3H)-trione)
- 10141-65-8(Uridine,5,6-dihydro-6-hydroxy- (9CI))
- 23067-10-9(5,6-Dihydro-5-methyluridine)
- 5626-99-3(5,6-Dihydro-2'-deoxyuridine)
- 19556-63-9(6-HYDROXYURIDINE))
- 14057-19-3( )
- 183617-36-9(Uridine, 5'-amino-5'-deoxy-5,6-dihydro-)
- 30100-83-5(5,6-Dihydro-ara-uridine)
- 109525-66-8(Uridine,2'-deoxy-5,6-dihydro-5,6-dihydroxy-, (5S,6S)- (9CI))
